Pharma BD Deal Intelligence
Johnson & Johnson acquired Momenta Pharmaceuticals for approximately $6.5 billion ($52.50 per share in cash) via tender offer and merger, completed October 1, 2020, gaining nipocalimab (M281), an anti-FcRn antibody targeting autoantibody-driven diseases. The acquisition thesis has since been validated: on April 30, 2025 the FDA approved nipocalimab as IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 and older who are anti-AChR or anti-MuSK antibody positive -- the first and only FcRn blocker approved across both antibody subtypes, based on the Phase 3 Vivacity-MG3 study. J&J is pursuing label expansion: it submitted an sBLA for warm autoimmune hemolytic anemia (wAIHA) in February 2026 (ENERGY Phase 2/3), for which the FDA granted Priority Review on April 27, 2026 as the potential first-ever approved wAIHA therapy, and nipocalimab holds Fast Track designation in Sjogren's disease. The asset has moved from pre-commercial pipeline to an approved, multi-indication FcRn franchise.